|
Adrenal Hyperplasia, Congenital
|
D000312 |
[A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.
] |
|
Adrenal Insufficiency
|
D000309 |
[Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.
] |
|
Adrenal Medulla
|
D000313 |
[The inner portion of the adrenal gland. Derived from ECTODERM, adrenal medulla consists mainly of CHROMAFFIN CELLS that produces and stores a number of NEUROTRANSMITTERS, mainly adrenaline (EPINEPHRINE) and NOREPINEPHRINE. The activity of the adrenal medulla is regulated by the SYMPATHETIC NERVOUS SYSTEM.
] |
|
Adrenal Rest Tumor
|
D000314 |
[Neoplasm derived from displaced cells (rest cells) of the primordial ADRENAL GLANDS, generally in patients with CONGENITAL ADRENAL HYPERPLASIA. Adrenal rest tumors have been identified in TESTES; LIVER; and other tissues. They are dependent on ADRENOCORTICOTROPIN for growth and adrenal steroid secretion.
] |
|
Adrenalectomy
|
D000315 |
[Excision of one or both adrenal glands. (From Dorland, 28th ed)
] |
|
Adrenarche
|
D050499 |
[A stage of development at which the ADRENAL GLANDS undergo maturation leading to the capability of producing increasing amounts of adrenal androgens, DEHYDROEPIANDROSTERONE and ANDROSTENEDIONE. Adrenarche usually begins at about 7 or 8 years of age before the signs of PUBERTY and continues throughout puberty.
] |
|
Adrenergic Agents
|
D018663 |
[Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
] |
|
Adrenergic Agonists
|
D000322 |
[Drugs that bind to and activate adrenergic receptors.
] |
|
Adrenergic Antagonists
|
D018674 |
[Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.
] |
|
Adrenergic Fibers
|
D000320 |
[Nerve fibers liberating catecholamines at a synapse after an impulse.
] |
|
Adrenergic Neurons
|
D059331 |
[Neurons whose primary neurotransmitter is NOREPINEPHRINE.
, Neurons whose primary neurotransmitter is EPINEPHRINE.
] |
|
Adrenergic Uptake Inhibitors
|
D018759 |
[Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
] |
|
Adrenergic alpha-1 Receptor Agonists
|
D058646 |
[Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS.
] |
|
Adrenergic alpha-1 Receptor Antagonists
|
D058668 |
[Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.
] |
|
Adrenergic alpha-2 Receptor Agonists
|
D058647 |
[Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.
] |
|
Adrenergic alpha-2 Receptor Antagonists
|
D058669 |
[Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS.
] |
|
Adrenergic alpha-Agonists
|
D000316 |
[Drugs that selectively bind to and activate alpha adrenergic receptors.
] |
|
Adrenergic alpha-Antagonists
|
D000317 |
[Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
] |
|
Adrenergic beta-1 Receptor Agonists
|
D058665 |
[Compounds that bind to and activate ADRENERGIC BETA-1 RECEPTORS.
] |
|
Adrenergic beta-1 Receptor Antagonists
|
D058671 |
[Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
] |
